A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

ClinicalTrials.gov ID: NCT00002184

Public ClinicalTrials.gov record NCT00002184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patients With CD4 Cell Counts >= 100/mm3 and HIV-1 RNA Copy Numbers >= 5,000 Copies/Ml and Prior RTI Therapy But No Prior PI Therapy

Study identification

NCT ID: NCT00002184
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Gilead Sciences; Industry
Enrollment: 120 participants

Conditions and interventions

Conditions

HIV Infections

Interventions

Nelfinavir mesylate Drug
Levocarnitine Drug
Adefovir dipivoxil Drug
Saquinavir Drug
Lamivudine Drug
Stavudine Drug
Zidovudine Drug

Drug

Eligibility (public fields only)

Age range: 16 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Not listed
Primary completion: Not listed
Completion: Not listed
Last update posted: Jun 23, 2005

United States locations

U.S. sites: 13
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
Phoenix Body Positive	Phoenix	Arizona	85016	—
Krauss Med Partners / Dept of Research and Development	Los Angeles	California	90036	—
UCLA Care Ctr	Los Angeles	California	900951793	—
Davies Med Ctr	San Francisco	California	94114	—
Blick Med Associates	Greenwich	Connecticut	06830	—
George Washington Med Ctr	Washington D.C.	District of Columbia	20037	—
Johns Hopkins Univ School of Medicine	Baltimore	Maryland	21287	—
Univ of Massachusetts Med Ctr	Worcester	Massachusetts	01655	—
North Shore Community Hosp	Manhassett	New York	11030	—
Associates of Med and Mental Health	Tulsa	Oklahoma	74114	—
Univ of Pennsylvania	Philadelphia	Pennsylvania	19104	—
Mem Hosp of Rhode Island	Pawtucket	Rhode Island	02860	—
Univ of Texas Southwestern Med Ctr of Dallas	Dallas	Texas	75235	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00002184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 23, 2005 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002184 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →